Who owns Kodiak Sciences Inc. (KOD)? Elite investor 13F holders

3 tracked elite investors reported holding Kodiak Sciences Inc as of 2026-09-30, including D.E. Shaw, Renaissance Technologies LLC, Polen Capital Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

3 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
D.E. ShawKODIAK SCIENCES INCSHARE2026-09-302026-11-16 00:00:0013245171.00 USD139717.000000SharesreduceOriginal filing
Renaissance Technologies LLCKODIAK SCIENCES INCSHARE2026-09-302026-11-12 00:00:008617320.00 USD90900.000000SharesreduceOriginal filing
Polen Capital ManagementKODIAK SCIENCES INCSHARE2026-09-302026-11-13 00:00:002298331.00 USD24244.000000SharesreduceOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown